Subjectivité agissante et entretien d’explicitation

Recherche et formation : La notion de subjectivité est centrale dans votre parcours de chercheur. À quel moment et comment a-t-elle émergé ? Pierre Vermersch : En fait je n’ai pas démarré (1969) par la notion de subjectivité. Elle n’est apparue en tant que telle que tardivement, en particulier à travers mes contacts avec les philosophes phénoménologues à la fin des années quatre-vingt-dix. En tant que psychologue, j’ai été motivé, et j’ai travaillé essentiellement dans le but de comprendre le..

Etude de l'expérience du sujet pour l'évaluation de nouvelles technologies ;: l'exemple d'une communication médiée.

26 pagesThis text presents the interest of studying the subjective dimension of the cognitive and affective processes of users by an experiential methodology, based on their description of their lived experience. A case study decribes the use of a audio-video communication tool for mobile and remote interactions. Data, obtained by interviews (explicitation and self-confrontation) and by the video recording of the activity, are analysed in terms of cognitive and emotional moves of the users during three sequences of interactions. They indicate the complementarity of analysing the observable behavior and the subjective reports.Dans cet article est décrit l'intérêt d'étudier la dimension subjective des processus cognitifs et affectifsdes utilisateurs par une méthode expérientielle, basée sur la description de leur vécu par les utilisateurs. Une étude de cas décrit l'utilisation effective d'un instrument de communication audio et vidéo pour les interactions mobiles à distance. Les données, obtenues par des entretiens approfondis (explicitation et auto-confrontation) et l'enregistrement vidéo de l'activité, sont analysées en terme des mouvements cognitifs et émotionnels des utilisateurs durant trois séquences d'interaction. L'analyse de ces données met en évidence l'inconfortable dissymétrie générée par l'outil dans le contrôle de l'exploration visuelle, la difficulté à suivre les mouvements imprévisibles de l'autre, et la compensation d'états affectifs co-occurents. La discussion développe l'apport d'une méthodologie expérientielle pour étudier l'émergence des affects et leur rôle fonctionnel pendant l'activité, en regard de l'action et de la décision

(65) Cybele is the smallest asteroid at hydrostatic equilibrium, why?

Context - Cybele asteroids constitute an appealing reservoir of primitive material genetically linked to the outer Solar system. The physical properties (size, shape) of the largest members can be directly measured with high-angular resolution imagers mounted on large (8-m class) telescopes.Aim - We took advantage of the bright apparition of the most iconic member of the Cybele population, (65) Cybele, in July and August 2021 to acquire high angular resolution images and optical light curves of the asteroid that were used to analyze its shape, topography and bulk properties (volume, density).Methods - Eight series of images were acquired with SPHERE+ZIMPOL on the Very Large Telescope (ESO Program ID 107.22QN.001; PI: Marsset) and combined with optical light curves to reconstruct the shape of the asteroid using the ADAM (Viikinkoski et al. 2015), MPCD (Capanna et al. 2013) and SAGE (Bartczak & Dudziński 2018) algorithms.Results - We will present Cybele's bulk properties, including its volume-equivalent diameter and average density, in the context of other low-albedo P-type asteroids. We will show that Cybele's shape and rotation state are entirely compatible to those of a Maclaurin equilibrium figure, opening up the possibility that D≥260 km (M≥1.4x10^19 kg) small bodies from the outer Solar System formed at equilibrium. We will further present the results of N-body simulations used to explore whether the equilibrium shape of Cybele is the result of a large resetting impact (similarly to the case of Hygiea; Vernazza et al. 2020), or if it is primordial (i.e., the result of early internal heating due to the radioactive decay of short- and long-lived radionuclides)

The equilibrium shape of (65) Cybele: primordial or relic of a large impact?

Context. Cybele asteroids constitute an appealing reservoir of primitive material genetically linked to the outer Solar System, and the physical properties (size and shape) of the largest members can be readily accessed by large (8m class) telescopes. Aims. We took advantage of the bright apparition of the most iconic member of the Cybele population, (65) Cybele, in July and August 2021 to acquire high-angular-resolution images and optical light curves of the asteroid with which we aim to analyse its shape and bulk properties. Methods. Eight series of images were acquired with VLT/SPHERE+ZIMPOL, seven of which were combined with optical light curves to reconstruct the shape of the asteroid using the ADAM, MPCD, and SAGE algorithms. The origin of the shape was investigated by means of N-body simulations. Results. Cybele has a volume-equivalent diameter of 263±3 km and a bulk density of 1.55 ± 0.19 g cm−3. Notably, its shape and rotation state are closely compatible with those of a Maclaurin equilibrium figure. The lack of a collisional family associated with Cybele and the higher bulk density of that body with respect to other large P-type asteroids suggest that it never experienced any large disruptive impact followed by rapid re-accumulation. This would imply that its present-day shape represents the original one. However, numerical integration of the long-term dynamical evolution of a hypothetical family of Cybele shows that it is dispersed by gravitational perturbations and chaotic diffusion over gigayears of evolution. Conclusions. The very close match between Cybele and an equilibrium figure opens up the possibility that D ≥ 260 km (M ≥ 1.5 × 1019 kg) small bodies from the outer Solar System all formed at equilibrium. However, we cannot currently rule out an old impact as the origin of the equilibrium shape of Cybele. Cybele itself is found to be dynamically unstable, implying that it was ‘recently’ (<1 Gyr ago) placed on its current orbit either through slow diffusion from a relatively stable orbit in the Cybele region or, less likely, from an unstable, Jupiter-family-comet orbit in the planet-crossing region.This work has been supported by the Czech Science Foundation through grants 20-08218S (J. Hanuš) and 21-11058S (M. Brož), as well as by the National Science Foundation under Grant No. 1743015 (F. Marchis). T. Santana-Ros acknowledges funding from the NEO-MAPP project (H2020-EU-2-1-6/870377). In addition, this work was partially funded by the Spanish MICIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” by the “European Union” through grant RTI2018-095076-B-C21, and the Institute of Cosmos Sciences University of Barcelona (ICCUB, Unidad de Excelencia ‘María de Maeztu’) through grant CEX2019-000918-M. This research has made use of the Asteroid Families Portal maintained at the Department of Astronomy, University of Belgrade. TRAPPIST is a project funded by the Belgian Fonds (National) de la Recherche Scientifique (F.R.S.-FNRS) under grant PDR T.0120.21. TRAPPIST-North is a project funded by the University of Liège, in collaboration with the Cadi Ayyad University of Marrakech (Morocco). E. Jehin is F.R.S.-FNRS Senior Research Associate

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR&nbsp;=&nbsp;2.05, 95%CI&nbsp;=&nbsp;1.39–3.02, p&nbsp;&lt;&nbsp;0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR&nbsp;=&nbsp;0.42, 95%CI&nbsp;=&nbsp;0.18–0.99, p&nbsp;=&nbsp;0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon

Aide à l'explication et retour réflexif

cote interne IRCAM: Vermersch04bNone / NoneNational audienceAide à l'explication et retour réflexi

Exemple d'utilisation du schéma d'analyse des effets des relances (actes, attention, état interne)

cote interne IRCAM: Vermersch04cNone / NoneNational audienceExemple d'utilisation du schéma d'analyse des effets des relances (actes, attention, état interne